期刊：
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING,2021年24(1):129-138 ISSN：1386-2073
通讯作者：
Tian, XF
作者机构：
[Tian, Xuefei; Tian, XF; Zhang, Zhen] Hunan Univ Chinese Med, Coll Integrated Chinese & Western Med, Dept Internal Med, Changsha 410208, Hunan, Peoples R China.;[Tian, Xuefei; Tian, XF; Zhang, Zhen; Wu, Ruoxia] Hunan Univ Chinese Med, Hunan Key Lab TCM Prescript & Syndromes Translat, Changsha 410208, Peoples R China.;[Deng, Tianhao; Zeng, Puhua; Chen, Siqin] Hunan Acad Tradit Chinese Med, Afilliated Hosp, Changsha 410006, Peoples R China.;[Gao, Wenhui; Wu, Ruoxia] Hunan Univ Chinese Med, Sch Chinese Med, Changsha 410208, Peoples R China.
通讯机构：
[Tian, XF ] H;Hunan Univ Chinese Med, Coll Integrated Chinese & Western Med, Dept Internal Med, Changsha 410208, Hunan, Peoples R China.;Hunan Univ Chinese Med, Hunan Key Lab TCM Prescript & Syndromes Translat, Changsha 410208, Peoples R China.
关键词：
Antitumor activity;Calculus bovis;Chemotherapy;Chinese medicine;Network pharmacology;Primary liver cancer
摘要：
<jats:sec><jats:title>Aim and Objective:</jats:title><jats:p>Calculus Bovis (CB) has been employed to treat diseases for a long time. It has been identified to play significant anti-inflammatory and anti-tumor roles. However, the mechanism of treating primary liver cancer (PLC) remains to be revealed. This study aims to clarify the molecules and mechanisms of CB in treating PLC.</jats:p></jats:sec><jats:sec><jats:title>Materials and Methods:</jats:title><jats:p>After oral bioavailability (OB) and drug-likeness (DL) screening, 15 small molecules were identified as the potential ingredients against PLC. Following this, related targets network constructions and pathways were applied to clarify the mechanism of CB in treating PLC. An in vitro experiment was carried out to identify the function of CB in treating PLC.</jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p>Eleven compounds of CB were identified that play an anti-PLC role, including oleanolic acid, ergosterol, ursolic acid, etc. The potential targets which were observed include IL6, MAPK-8, VEGFA, Caspase-3, etc. Further analysis showed that the mechanism of CB in the treatment of PLC involved apoptosis-related pathways and immune-related pathways.</jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p>In summary, the current study combines network pharmacology and in vitro experiments to reveal the mechanism of CB against PLC. We concluded that 11 ingredients of CB have an anti-PLC effect. Furthermore, CB plays a key role in treating PLC mainly by apoptosisrelated pathways and immune-related pathways. Our experiment verifies that CB promotes the apoptosis of SMMC-7721.</jats:p></jats:sec>
摘要：
目的探讨加味丹参饮通过调节鸟氨酸脱羧酶（ODC）活性在抗SD大鼠心肌缺血再灌注损伤（IRI）中的保护机制。方法建立SD大鼠心肌IRI模型,设对照组、假手术组、缺血再灌注损伤（IRI）组、加味丹参饮（JWDSY）+IRI组共4组。酶联免疫（ELISA）法测定ODC含量,实时荧光定量PCR（RT-PCR）方法检测ODC m RNA表达水平,免疫印迹（Western blot）法检测ODC蛋白表达水平,高效液相色谱检测心肌组织中多胺的含量。结果与对照组比较,假手术组的ODC含量、ODC m RNA及蛋白表达水平均无统计学意义（P>0.05）;与假手术组比较,IRI组的ODC含量显著增加、ODC m RNA及蛋白表达水平显著升高,差异有统计学意义（P<0.01）;与IRI组比较,JWDSY+IRI组ODC含量显著减少,ODC m RNA和蛋白表达水平显著降低,差异有统计学意义（P<0.01）。结论加味丹参饮可能通过调节ODC活性,从而发挥对IRI后心肌的保护作用。
